article thumbnail

The latest drug discovery product launches

Drug Discovery World

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

article thumbnail

Listicle: Maximising outsourcing models beyond time and cost

Drug Discovery World

During a 2021 webinar on optimising assay development for hit identification, a survey asked over 50 drug discovery scientists, “Which goal is the highest priority when developing a drug discovery assay?”. Minimising reagent consumption and costs. Generating robust, reproducible data generating confidence in results.

Reagent 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Up to 8 recipients to be awarded grants for genomic research

Drug Discovery World

Beckman Coulter Life Sciences has released a call for registrations for its SPRI Grants for Genomic Research, which the company describes as part of its commitment to the next generation of researchers and scientists. .

Genome 52
article thumbnail

Next-gen antibody discovery: Leveraging DNA immunisation

Drug Discovery World

Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for next-generation antibody production. These qualities make them ideal for both therapeutic applications and diagnostic reagents.

DNA 52
article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

article thumbnail

Busting common myths about lab automation 

Drug Discovery World

Valuable scientists may also become bored and look for more exciting work elsewhere that makes better use of their education and skills. If you perform all of your tasks manually, you may need to stop your initial run partway through, which means losing the reagents and samples with which you have already begun working.

Reagent 111
article thumbnail

Busting common myths about lab automation 

Drug Discovery World

Many automation solutions can perform several different tasks and can be paired with other equipment to automate a range of tasks, such as DNA extraction and sequencing, PCR, and Western blots. Valuable scientists may also become bored and look for more exciting work elsewhere that makes better use of their education and skills.

Reagent 98